BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schreiber S, Ben-Horin S, Alten R, Westhovens R, Peyrin-Biroulet L, Danese S, Hibi T, Takeuchi K, Magro F, An Y, Kim DH, Yoon S, Reinisch W. Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. Adv Ther 2022;39:2342-64. [PMID: 34988877 DOI: 10.1007/s12325-021-01990-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Kalpachidou T, Riehl L, Schöpf CL, Ucar B, Kress M. Proinflammatory cytokines and their receptors as druggable targets to alleviate pathological pain. PAIN 2022;163:S79-S98. [DOI: 10.1097/j.pain.0000000000002737] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Alten R, An Y, Kim DH, Yoon S, Peyrin-Biroulet L. Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit. Clin Drug Investig 2022;42:477-89. [PMID: 35657560 DOI: 10.1007/s40261-022-01162-6] [Reference Citation Analysis]